Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Pediatric Endocrinology

Managing Neonatal Diabetes and Exocrine Pancreatic Insufficiency

At a Glance

In GATA6 syndrome, a small or absent pancreas can cause both neonatal diabetes and exocrine pancreatic insufficiency. Care combines carefully monitored insulin, pancreatic enzymes when EPI is confirmed, high-energy nutrition, vitamin support, and emergency planning.

Because GATA6 syndrome often results in a pancreas that is smaller than normal or missing entirely, your child’s body may struggle with two distinct but related tasks: regulating blood sugar and digesting food [1]. Managing these conditions—neonatal diabetes and exocrine pancreatic insufficiency (EPI)—requires a coordinated approach where a change in one often affects the other [2].

Managing Digestion (Exocrine Pancreatic Insufficiency)

The pancreas produces enzymes that break down fats, proteins, and carbohydrates. Without these enzymes, food passes through the body without being absorbed, leading to poor weight gain and digestive distress [3].

  • Enzyme Replacement Therapy (PERT): The “cornerstone” of treatment is Pancreatic Enzyme Replacement Therapy (PERT) [4]. However, this is only necessary if testing confirms EPI. The dose is prescribed in lipase units and must be administered carefully—infants often receive opened capsules mixed into a specific acidic soft food like applesauce, and the beads must never be crushed or chewed. These are specialized capsules taken at the start of every meal, snack, or breastfeeding/bottle session [4][5]. These enzymes act as a “pancreas in a bottle,” doing the work the body cannot do on its own [6].
  • A High-Energy Diet: Unlike some other digestive conditions, children with EPI should not have their fat intake restricted [3]. In fact, an adequate, high-energy diet is essential for proper growth and development, but must be individualized by a pediatric dietitian based on the child’s cardiac and diabetes status [7].
  • Vitamin Support: Because the body cannot absorb fat correctly, it also struggles to absorb fat-soluble vitamins—Vitamins A, D, E, and K [4][8]. Your care team will monitor these levels and likely prescribe specific supplements to prevent deficiencies that could affect bone health or vision [4][9].

Managing Blood Sugar (Neonatal Diabetes)

In infants, diabetes is often “labile,” meaning blood sugar levels can swing rapidly from very high to very low [2]. Because babies eat frequently and have very small bodies, even a tiny amount of insulin has a large effect [10].

  • Continuous Glucose Monitors (CGM): These small sensors under the skin provide real-time blood sugar readings every few minutes [2]. They are vital for detecting “silent” highs or lows that might be missed between finger-prick tests [11].
  • Insulin Pumps (CSII): For many infants, an insulin pump (or Continuous Subcutaneous Insulin Infusion) is the preferred way to deliver insulin [12]. Pumps allow for “micro-dosing,” providing the tiny, precise amounts of insulin an infant needs more safely than traditional injections [13][14]. While often preferred depending on age and device approval, technology requires clinical oversight. Pump interruptions can cause rapid insulin deficiency, requiring a backup injection plan.
  • The Absorption Connection: It is important to know that as digestion improves with PERT, the body absorbs more carbohydrates from food. This often means that as your child’s digestion gets better, their insulin needs will increase or decrease [2]. Glucose should be monitored closely and doses adjusted only per a written endocrinology plan.

Emergency Signs & Red Flags

Infants cannot tell you how they feel, so you must watch for physical signals. Always follow the specific emergency plan provided by your medical team. Obtain a written sick-day plan covering when to check ketones and when to seek emergency help. Never stop basal insulin independently.

Call Your Doctor or Seek Urgent Care If:

  • Growth Concerns: Your child is not gaining weight, is losing weight, or seems to be “stalling” in their growth [3].
  • Digestive Distress: Stools are consistently oily, foul-smelling, or float, which may mean the PERT dose needs adjustment [3].
  • Persistent Highs: Blood sugar is consistently higher than the target range set by your doctor, even after extra insulin “corrections.”

Go to the Emergency Room (ER) Immediately If:

1. Severe Low Blood Sugar (Hypoglycemia):

  • Your child is unusually sleepy, difficult to wake, or “floppy.”
  • Extreme fussiness or crying that cannot be calmed.
  • Pale skin, sweating, or seizures [15][16].
  • Action: If your child is unconscious or cannot swallow, use your emergency glucagon kit as instructed by your doctor and call emergency services. Do not put anything in the mouth of an unconscious child.

2. Diabetic Ketoacidosis (DKA):
This is a life-threatening condition where the body becomes too acidic because it lacks insulin [17].

  • Vomiting or inability to keep fluids down [18].
  • Rapid, heavy breathing (like they are running a race while lying down) [17].
  • A “fruity” smell on their breath.
  • Signs of severe dehydration (no wet diapers for several hours, no tears when crying, or a sunken “soft spot” on the head) [17].
  • Action: Go to the nearest ER immediately. DKA in infants can progress to shock or death very quickly if not treated with IV fluids and insulin [19][17].

A Note on Remission

In some children with GATA6 mutations, the diabetes may seem to “go away” for months or years—a period called remission [20]. However, because the pancreas remains small, the diabetes can return (or be permanent or transient), often during the stress of puberty or an illness [20]. Even during remission, occasional monitoring of blood sugar remains a part of lifelong care [20]. Recurrence is possible but timing cannot be predicted.

Common questions in this guide

Why can GATA6 syndrome cause both neonatal diabetes and digestive problems?
GATA6 mutations can cause the pancreas to be unusually small or absent. Because the pancreas makes both insulin and digestive enzymes, reduced pancreatic tissue can lead to neonatal diabetes and exocrine pancreatic insufficiency.
Does every baby with GATA6 syndrome need pancreatic enzyme replacement?
No. Pancreatic enzyme replacement therapy, or PERT, is needed when testing confirms exocrine pancreatic insufficiency. The care team prescribes the dose and usually gives it with every meal, snack, or feeding.
How should pancreatic enzymes be given to an infant?
Infant capsules may be opened and the enzyme beads mixed with a prescribed acidic soft food, such as applesauce, before feeding. The beads should not be crushed or chewed, and the exact method and dose should come from the child’s care team.
How is neonatal diabetes managed in a baby with GATA6 syndrome?
Care may include a continuous glucose monitor and an insulin pump, which can deliver very small doses. Because glucose can change quickly and a pump can stop working or disconnect, families need close clinical oversight, frequent monitoring, and a written backup injection plan.
What signs of low blood sugar or diabetic ketoacidosis require emergency care?
An infant who is difficult to wake, floppy, having a seizure, or unable to swallow may have severe low blood sugar and needs emergency action. Vomiting, rapid heavy breathing, fruity-smelling breath, or severe dehydration can signal diabetic ketoacidosis and require immediate emergency care. Use emergency glucagon only as instructed by the medical team, and never give anything by mouth to an unconscious child.
Which vitamins may need monitoring when an infant has exocrine pancreatic insufficiency?
Poor fat absorption can reduce vitamins A, D, E, and K. The care team may check vitamin levels and prescribe supplements, with the specific doses based on the child’s results and needs.
Can GATA6-related neonatal diabetes go away and come back?
Some children have a period of remission lasting months or years, but diabetes may be transient, permanent, or return later. Illness or puberty may bring recurrence, so blood sugar monitoring remains important even during remission.

Get notified when new evidence is published on Pancreatic hypoplasia-diabetes-congenital heart disease syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Case report: adult onset diabetes with partial pancreatic agenesis and congenital heart disease due to a de novo GATA6 mutation.

    Sanchez-Lechuga B, Saqlain M, Ng N, et al.

    BMC medical genetics 2020; (21(1)):70 doi:10.1186/s12881-020-01012-2.

    PMID: 32245430
  2. 2

    Successful Treatment of a Very Low-Birth-Weight Infant With GATA6 Neonatal Diabetes Using Continuous Subcutaneous Insulin Infusion.

    Ito T, Suzuki A, Yamaguchi N, et al.

    Cureus 2025; (17(5)):e83555 doi:10.7759/cureus.83555.

    PMID: 40476119
  3. 3

    Management of Exocrine Pancreatic Insufficiency in Children.

    Sankararaman S, Schindler T, Sferra TJ

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2019; (34 Suppl 1()):S27-S42 doi:10.1002/ncp.10388.

    PMID: 31535732
  4. 4

    Exocrine Pancreatic Insufficiency in Children - Challenges in Management.

    Sankararaman S, Schindler T

    Pediatric health, medicine and therapeutics 2023; (14()):361-378 doi:10.2147/PHMT.S402589.

    PMID: 37908317
  5. 5

    Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine.

    Ritivoiu ME, Drăgoi CM, Matei D, et al.

    Pharmaceutics 2023; (15(1)) doi:10.3390/pharmaceutics15010162.

    PMID: 36678791
  6. 6

    State of the Art in Exocrine Pancreatic Insufficiency.

    Diéguez-Castillo C, Jiménez-Luna C, Prados J, et al.

    Medicina (Kaunas, Lithuania) 2020; (56(10)) doi:10.3390/medicina56100523.

    PMID: 33036352
  7. 7

    Management of pancreatic exocrine insufficiency.

    Dominguez-Muñoz JE

    Current opinion in gastroenterology 2019; (35(5)):455-459 doi:10.1097/MOG.0000000000000562.

    PMID: 31219829
  8. 8

    Role of elexacaftor-tezacaftor-ivacaftor therapy on fecal elastase-1 and fat-soluble vitamins in children with cystic fibrosis.

    Eryilmaz Polat S, Özkan Tabakçı S, Bilgiç I, et al.

    European journal of pediatrics 2026; (185(2)):72.

    PMID: 41526774
  9. 9

    Nutritional Status in the First 2 Years of Life in Cystic Fibrosis Diagnosed by Newborn Screening.

    Munck A, Boulkedid R, Weiss L, et al.

    Journal of pediatric gastroenterology and nutrition 2018; (67(1)):123-130 doi:10.1097/MPG.0000000000001956.

    PMID: 29543697
  10. 10

    Management of Neonatal Diabetes due to a KCNJ11 Mutation with Automated Insulin Delivery System and Remote Patient Monitoring.

    Lee MY, Gloyn AL, Maahs DM, Prahalad P

    Case reports in endocrinology 2023; (2023()):8825724 doi:10.1155/2023/8825724.

    PMID: 37664823
  11. 11

    Management of a case of transient neonatal diabetes mellitus using continuous glucose monitoring.

    Iwata N, Asui R, Mizumoto H, Hata D

    Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2020; (29(2)):77-80 doi:10.1297/cpe.29.77.

    PMID: 32313376
  12. 12

    Insulin Delivery Technology for Treatment of Infants with Neonatal Diabetes Mellitus: A Systematic Review.

    Panza R, Cattivera V, Colella J, et al.

    Diabetes therapy : research, treatment and education of diabetes and related disorders 2024; (15(11)):2293-2308 doi:10.1007/s13300-024-01653-z.

    PMID: 39292435
  13. 13

    Successful treatment of young infants presenting neonatal diabetes mellitus with continuous subcutaneous insulin infusion before genetic diagnosis.

    Rabbone I, Barbetti F, Marigliano M, et al.

    Acta diabetologica 2016; (53(4)):559-65 doi:10.1007/s00592-015-0828-7.

    PMID: 26831749
  14. 14

    Very low birth weight newborn with diabetes mellitus due to pancreas agenesis managed with insulin pump reservoir filled with undiluted insulin: 16-month follow-up.

    Zanfardino A, Piscopo A, Curto S, et al.

    Diabetes & metabolic syndrome 2022; (16(7)):102561 doi:10.1016/j.dsx.2022.102561.

    PMID: 35809554
  15. 15

    Hyperglycaemia-related complications at the time of diagnosis can cause permanent neurological disability in children with neonatal diabetes.

    Day JO, Flanagan SE, Shepherd MH, et al.

    Diabetic medicine : a journal of the British Diabetic Association 2017; (34(7)):1000-1004 doi:10.1111/dme.13328.

    PMID: 28173619
  16. 16

    Clinical characteristics, growth patterns, and long-term diabetes complications of 24 patients with neonatal diabetes mellitus: A single center experience.

    Mouler M, Lebenthal Y, de Vries L, et al.

    Pediatric diabetes 2022; (23(1)):45-54 doi:10.1111/pedi.13295.

    PMID: 34837310
  17. 17

    Fulminant non-autoimmune diabetes presenting as fatal diabetic ketoacidosis in a 2-month-old infant with genetically confirmed Wolcott-Rallison syndrome.

    Akçay N, Bingöl İ, Tosun D

    Diabetic medicine : a journal of the British Diabetic Association 2026;.

    PMID: 42945448
  18. 18

    Not All Diabetic Ketoacidosis in Infant Is Type 1: A Case Report Permanent Neonatal Diabetes.

    Al Homyani DK, Al Homaiani L

    AACE clinical case reports 2024; (10(1)):7-9 doi:10.1016/j.aace.2023.10.004.

    PMID: 38303767
  19. 19

    Successful Treatment of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Status in an Infant with KCNJ11-Related Neonatal Diabetes Mellitus via Continuous Renal Replacement Therapy.

    Chen T, Zhang D, Bai Z, et al.

    Diabetes therapy : research, treatment and education of diabetes and related disorders 2018; (9(5)):2179-2184 doi:10.1007/s13300-018-0484-3.

    PMID: 30094785
  20. 20

    Clinical Characteristics and Remission Monitoring of 6q24-Related Transient Neonatal Diabetes.

    McCullough ME, Letourneau-Freiberg LR, Bowden TL, et al.

    Pediatric diabetes 2024; (2024()):3624339 doi:10.1155/pedi/3624339.

    PMID: 40302951

This page provides general information about managing GATA6-related neonatal diabetes and exocrine pancreatic insufficiency for educational purposes only; it does not constitute medical advice. Follow your child’s individualized plan and contact the care team for guidance about specific symptoms, doses, and emergencies.